Methinks AI

Barcelona, Spain All Spain companies → — Founded 2016

Seed

Website Claim this company

Products

Methinks CTA Stroke

Methinks AI

Neurology AI

Methinks CTA Stroke is an FDA-cleared AI software that accurately detects suspected large vessel occlusions (LVOs) from CTA scans, including distal occlusions, with high sensitivity and specificity. It integrates with hospital systems and Microsoft Teams for real-time stroke triage and team coordination.

See all 1 product →

About Methinks AI

Methinks AI is a venture-backed digital health company specializing in AI-powered imaging assessment solutions for neurovascular emergencies, with a primary focus on stroke. Their mission is to provide universal and timely access to life-saving treatments through advanced and accessible technology. The company has developed AI software, Methinks Stroke Suite, which assists in stroke triage and provides decision support using non-contrast CT (NCCT) scans. This technology aims to optimize stroke triage and reduce time to treatment, significantly improving clinical outcomes. Methinks AI’s software is designed to detect large vessel occlusions (LVOs) and intracranial hemorrhages (ICH) from routine NCCT scans, even in their more subtle forms, and has received CE mark and FDA 510(k) clearance for this capability.

For physicians, Methinks AI’s solution integrates into existing hospital workflows, often via Microsoft Teams, to deliver real-time alerts and streamline communication among healthcare professionals. This allows for faster identification of suspicious stroke cases, enabling quicker coordination with stroke units and potentially reducing patient transfer times. The software’s ability to analyze NCCT scans is particularly beneficial in settings with limited access to advanced imaging technologies like CT angiography, making it a scalable solution for early stroke assessment globally. Methinks AI’s technology has been validated in hospitals across Europe and the U.S., demonstrating its potential to improve LVO detection and aid in critical decision-making for stroke care.

Focus Areas

AI-powered imaging assessment neurovascular emergencies stroke diagnosis large vessel occlusion (LVO) detection intracranial hemorrhage (ICH) detection stroke triage decision support medical imaging software non-contrast CT analysis CT angiography analysis telemedicine

Business Intelligence

Technology

AI algorithms for medical imaging analysis, cloud-based software, Microsoft Teams integration

What Physicians Need to Know

AI-Powered Imaging Assessment

Methinks AI offers AI-based software, the Methinks Stroke Suite, for radiological computer-aided triage and notification. It uses AI algorithms to identify suspected Large Vessel Occlusions (LVO) on non-contrast computed tomography (NCCT) images and computed tomography angiography (CTA), and also detects Intracerebral Hemorrhages (ICH) on NCCT images.

Neurovascular Emergencies & Stroke Diagnosis

The company's primary focus is on stroke, the second most common cause of death globally. Their AI solutions aim to provide early, rapid, and precise triaging of acute stroke patients, supporting physicians in crucial treatment and triage decisions in emergency cases.

LVO & ICH Detection

Methinks Stroke Suite is capable of detecting both hyperdense and non-hyperdense LVOs from NCCT and CTA, as well as identifying ICH from NCCT scans. Their CTA Stroke solution has demonstrated high sensitivity (98.2%) and specificity (91.6%) in detecting LVOs, including distal occlusions up to the MCA-M2 segment.

Stroke Triage & Decision Support

The software acts as a comprehensive triage solution, optimizing stroke patient triage and reducing time to treatment. It provides notifications of suspected ICH and LVO cases to assist trained physicians.

Medical Imaging Software & Non-Contrast CT Analysis

Methinks AI's solutions are designed to work with the simplest CT scans available in all hospitals, including non-contrast CT, making stroke assessment accessible even in low-resource settings. Their NCCT Stroke software is a first-of-its-kind tool cleared to detect suspected LVOs and ICH directly from routine CT scans.

CT Angiography Analysis

In addition to NCCT, Methinks AI also offers Methinks CTA Stroke, an AI-based software solution that accurately detects suspected LVOs using CT Angiography (CTA) scans.

Telemedicine & Communication

The solution integrates seamlessly with Microsoft Teams, allowing clinicians to view and share imaging instantly without additional software, expediting treatment decisions. This cloud-based communication system helps coordinate among hospitals, stroke units, and healthcare professionals.

Physician Tip

Methinks AI's solutions can significantly aid physicians by providing early, rapid, and precise detection of LVOs and ICH from both NCCT and CTA scans, including subtle distal occlusions often missed. This can lead to faster triage, reduced time to treatment, and improved patient outcomes, especially in emergency settings and hospitals with limited access to advanced imaging. The integration with Microsoft Teams facilitates real-time collaboration and decision-making among stroke teams. The ability to use widely available NCCT scans expands access to critical stroke assessment in various healthcare settings.

Methinks AI's software is built to seamlessly integrate into Microsoft Teams, providing an advanced medical imaging viewer directly within the collaborative environment. The solution runs on Microsoft Azure. Methinks AI has also partnered with Medtronic to enhance stroke treatment across Central and Eastern Europe, Africa, Türkiye, and the Middle East, integrating Methinks AI with Medtronic's stroke treatment portfolio.

Products by Methinks AI

1 product in the directory

Methinks CTA Stroke

Methinks AI

Neurology AI

What the Web Says

Methinks AI is a Barcelona-based health tech company specializing in AI-driven solutions for stroke detection and triage. Their software analyzes CT scans to detect large vessel occlusions (LVOs) and intracranial hemorrhages (ICH), aiming to expedite treatment and improve patient outcomes, particularly in hospitals without advanced imaging capabilities. The company has received FDA clearance for its NCCT Stroke and CTA Stroke modules and has partnered with Medtronic and Microsoft to expand its reach and integrate its technology into existing healthcare workflows.

Overall: Positive

Strengths

FDA-cleared for detecting LVOs and ICH from standard CT scans, including distal occlusions.
Can be deployed in any hospital with a standard CT scanner, reducing reliance on advanced imaging.
Integrates with existing hospital systems like PACS, RIS, and Microsoft Teams for seamless workflow.
Aims to significantly reduce time-to-treatment for stroke patients.
Partnerships with Medtronic and Microsoft enhance distribution and scalability.
High accuracy in detecting suspected large vessel occlusions (over 80%) with a low error rate.

Limitations

Limited public reviews available on major platforms like G2, Glassdoor, and Capterra specifically for their healthcare AI product.
Some general feedback for 'methinks' (a different entity focused on user testing) indicates a need for a larger user base for faster turnaround and infrequent new gigs for participants.
Pricing information for Methinks AI's healthcare solutions is not publicly available.
Reddit discussions mentioning 'methinks AI' are often unrelated to the healthcare product or are speculative.

Based on reviews from: saaskart.co, g2.com, capterra.ca, microsoft.com, apple.com, med-tech.world, arintoo.com, revenuebase.ai, rasph.com, flcube.com, reddit.com, xtalks.com

Last updated: 2026-11-01

Videos

News, demos, and interviews about Methinks AI.

Loading videos...

Videos load interactively. If none appear, search YouTube for Methinks AI →

View all on YouTube

Press & Coverage

methinks.ai

Methinks Receives CE Mark for Methinks Ischemia, Advancing AI Stroke Detection from Plain CT

Methinks announced that its Methinks Ischemia product received CE marking, allowing it to measure and visually highlight suspected ischemic changes directly from non-contrast CT scans, without requiring advanced imaging. This advancement aims to provide critical ischemic volume information to any hospital with a plain CT scanner to aid in stroke treatment decisions.

2026-10

methinks.ai

Methinks AI Secures Second FDA Clearance, Expanding its Stroke Detection Solution to Contrast Imaging

Methinks AI received its second FDA 510(k) clearance of the year for Methinks CTA Stroke, an AI-based software solution that accurately detects suspected large vessel occlusions (LVOs) using CT Angiography (CTA) scans. This clearance, following the earlier approval of Methinks NCCT Stroke, positions the company to enter the US market with a comprehensive stroke triage platform.

2025-10

neuronewsinternational.com

Methinks AI receives US FDA 510(k) clearance for NCCT Stroke software

Methinks AI announced that its non-contrast computed tomography (NCCT) Stroke software received 510(k) clearance from the US FDA. This software enhances NCCT detection capabilities for suspected large vessel occlusions (LVOs) and more distal occlusions, aiming to improve timely stroke treatment.

2025-07

nih.gov

Methinks AI software for identifying large vessel occlusion in non-contrast head CT: A pilot retrospective study in American population

This pilot retrospective study evaluated the performance of the Methinks AI algorithm for detecting large vessel occlusions (LVOs) in non-contrast head CT scans in a U.S. multi-facility stroke network. The study found that the Methinks LVO algorithm demonstrated 75% sensitivity and 83% specificity, showing promise for improving LVO detection, especially in resource-limited settings.

2025-07

medtronic.com

Medtronic announces strategic partnership with Methinks AI to advance stroke care development

Medtronic announced a strategic partnership with Methinks AI to enhance stroke treatment across Central and Eastern Europe, Africa, Turkey, and the Middle East. This collaboration integrates Methinks AI's solutions with Medtronic's neurovascular portfolio to streamline stroke workflows and improve patient outcomes.

2025-03

methinks.ai

Neuro-rescue secures €2.19M in public-private funding

Methinks Software announced the launch of Neuro-rescue, a project combining AI and telemedicine to accelerate the diagnosis and treatment of neurological conditions in non-specialized emergency departments. The initiative secured €2.19 million in funding from the Spanish State Research Agency (AEI).

2026-04

thenewbarcelonapost.com

The EIC Fund grants a participating loan to the company and commits to contributing up to five million in the Series A round it will raise in 2024.

The European Innovation Council (EIC) Fund has granted Methinks AI a participating loan and committed up to five million euros in equity investment for its Series A financing round in 2024. This funding supports Methinks' development of AI software for early stroke identification.

2023-11

prnewswire.com

Methinks receives CE Marked Certification for AI-based stroke triage software

Methinks announced it received CE mark for its medical imaging software, Methinks Stroke Suite, enabling commercialization in Europe. This software assists in finding large vessel occlusions (LVO) from non-contrast CT images, aiming to improve stroke patient outcomes.

2023-02

Frequently Asked Questions

What specific AI-powered imaging assessment products does Methinks AI offer for neurovascular emergencies, and what do they detect?

Methinks AI offers the Methinks Stroke Suite, which is designed for stroke triage and decision support. This software utilizes AI algorithms to detect suspected Large Vessel Occlusions (LVOs) and intracranial hemorrhages (ICH) on non-contrast CT (NCCT) images. It also assists in finding LVOs from CT angiography (CTA) scans. Methinks AI has also launched 'Neuro-rescue,' a project that uses AI to analyze non-contrast CT scans for early detection of neurological conditions like intracranial aneurysms, vascular occlusions, and brain hemorrhages.

How accurate and reliable are Methinks AI's stroke detection capabilities, particularly for LVO and ICH on non-contrast CT scans?

Methinks AI's NCCT Stroke software has demonstrated high accuracy in detecting suspected LVOs and ICH. For ICH detection, it has shown a sensitivity of 97.3% and specificity of 99.4%. For LVO detection on NCCT, studies have shown varying sensitivities, including 75% sensitivity and 83% specificity in one U.S. study, and 77% sensitivity and 93% specificity in another. The software is noted for its ability to detect more distal LVOs, such as those in the MCA-M2 segment, and has been shown to reduce false negatives by nearly 50% compared to other NCCT triage tools.

What are Methinks AI's regulatory clearances and compliance standards for its medical imaging software?

Methinks AI has received CE Mark certification for its Methinks Stroke Suite, making it the first CE-marked medical device to assist in finding LVOs from NCCT and CTA, and to detect ICH on NCCT. The company has also received FDA 510(k) clearance for its NCCT Stroke software, which detects suspected LVOs and intracranial hemorrhages directly from routine CT scans. Additionally, Methinks AI received a second FDA 510(k) clearance for Methinks CTA Stroke, an AI-based solution for detecting LVOs using CTA scans.

How does Methinks AI integrate with existing hospital workflows and telemedicine platforms, and what are the implications for stroke triage and decision support?

Methinks AI's solutions are designed to integrate seamlessly into hospital systems, including PACS and Microsoft Teams. This integration allows for real-time collaboration among stroke teams, enabling clinicians to view and share imaging instantly through Microsoft Teams without additional software. This streamlined communication and decision-making process helps optimize stroke triage, expedite treatment decisions, and improve patient outcomes, especially in telemedicine scenarios where rapid expert consultation is crucial.

What is Methinks AI's business model regarding pricing, customer support, and company stability?

While specific pricing details for Methinks AI's medical imaging software are not publicly disclosed, some general information about 'methinks' (which may or may not be the same entity or a related one) indicates a starting price of US$89.00 for a different type of software. Methinks AI is a privately held, venture capital-backed company founded in 2016 and headquartered in Barcelona, Spain. The company has raised $9.2M in funding. Methinks AI has established significant partnerships with companies like Medtronic, Microsoft, and Siemens Healthineers, which suggests a focus on scalability, accessibility, and broader market reach, contributing to its stability.

Related Companies

Suggest an Edit → | Report an issue